Long-term albendazole treatment in one case of alveolar echinococcosis: Case report
| dc.contributor.author | Çökmez A. | |
| dc.contributor.author | Aydede H. | |
| dc.contributor.author | Gür S. | |
| dc.contributor.author | Tarcan E. | |
| dc.date.accessioned | 2025-04-10T11:17:46Z | |
| dc.date.available | 2025-04-10T11:17:46Z | |
| dc.date.issued | 2003 | |
| dc.description.abstract | Aims: Curative therapy of alveolar echinococcosis is total surgical removal of the infected tissue and concomitant chemotherapy. However, this curative resection can be done on a limited number of patients, for the remaining ones various palliative procedures can be performed. Method: In this article it is aimed to present the result of long-term albendazole treatment in patient who had a palliative hepatojejunostomy for obstructive jaundice due to unresectable alveolar echinococcosis. Results: Systemic albendazole treatment was initiated in this patient after palliative hepatojejunostomy procedure. During follow up there was no abnormality in blood chemistry and a considerable regression in size of the lesion was found in postoperative month 24. Residual hepatic lesion was histopathologically documented and showed apparently non-viable parasitic cysts by biopsy. These findings suggest the long-term albendazole therapy being parasitocidal. Conclusions: Palliative or mass reduction surgery combined with long-term albendazole therapy is the standard therapy for advanced disease, especially when curative resection might result in significant morbidity and mortality. | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/52906 | |
| dc.title | Long-term albendazole treatment in one case of alveolar echinococcosis: Case report | |
| dc.type | Article |